Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 92

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 92
---
 |     |   |            362,533 |
| Accrued Payroll        |     |   |      1,256,630 |     |   |          1,256,630 |
| Accrued Rent           |     |   |         40,000 |     |   |                  - |
| Other Accrued Expenses |     |   |         41,423 |     |   |             41,423 |
| Total                  |     | $ |      1,752,508 |     | $ |          1,664,827 |

6. UNEARNED INCOME

Unearned income is attributable to payments made to the Company and its wholly owned subsidiary pursuant to two license agreements for which income is recognized over the terms of the agreement.

| 76 |

7. NOTES PAYABLE

Notes Payable comprise of below:

(a) RELATED PARTY

Notes payable to related parties consisted of the following:

SCHEDULE OF NOTES PAYABLE TO RELATED PARTIES

|                                        |     |   |          As of 
 March 31, 2025 |     |   |                 As 
                 of 
 September 30, 2024 |
|:---------------------------------------|:----|:--|---------------:|:----|:--|-------------------:|
| David Koos                             |     | $ |         63,948 |     | $ |              1,708 |
| BST Partners                           |     |   |         87,215 |     |   |                  - |
| Zander Therapeutics, Inc.              |     |   |         59,200 |     |   |             40,000 |
| Total notes payable to related parties |     | $ |        210,363 |     | $ |             41,708 |

$63,948 lent to the Company by David Koos is due and payable at the demand of the holder and bears simple interest at a rate of 15% per annum.

$15,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on May 3. 2025 and bears simple interest at a rate of 10% per annum.

$25,000 lent to the Company by Zander Therapeutics, Inc. is due and payable on June 5. 2025 and bears simple interest at a rate of 10% per annum.

$10,000 lent to the Company by Zander Therapeutics, Inc. is due